154 related articles for article (PubMed ID: 19887483)
1. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Taplin ME; Regan MM; Ko YJ; Bubley GJ; Duggan SE; Werner L; Beer TM; Ryan CW; Mathew P; Tu SM; Denmeade SR; Oh WK; Sartor O; Mantzoros CS; Rittmaster R; Kantoff PW; Balk SP
Clin Cancer Res; 2009 Nov; 15(22):7099-105. PubMed ID: 19887483
[TBL] [Abstract][Full Text] [Related]
2. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
3. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Shah SK; Trump DL; Sartor O; Tan W; Wilding GE; Mohler JL
J Urol; 2009 Feb; 181(2):621-6. PubMed ID: 19091347
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
6. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
Sartor O; Nakabayashi M; Taplin ME; Ross RW; Kantoff PW; Balk SP; Oh WK
Clin Genitourin Cancer; 2009 Oct; 7(3):E90-2. PubMed ID: 19815488
[TBL] [Abstract][Full Text] [Related]
7. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
8. [Dutasteride in the treatment of hormone refractory prostate cancer].
Arena F
Minerva Urol Nefrol; 2008 Jun; 60(2):71-6. PubMed ID: 18500220
[TBL] [Abstract][Full Text] [Related]
9. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
10. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
12. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
14. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
15. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
18. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.
Trump DL; Havlin KH; Messing EM; Cummings KB; Lange PH; Jordan VC
J Clin Oncol; 1989 Aug; 7(8):1093-8. PubMed ID: 2474059
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.
Hamid AR; Verhaegh GW; Smit FP; van Rijt-van de Westerlo C; Armandari I; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
J Urol; 2015 Mar; 193(3):1023-9. PubMed ID: 25242390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]